Alnylam Pharmaceuticals (NASDAQ:ALNY) doesn't have a drug on the market yet, but it was a busy second quarter for the biotech, with movement on the pipeline front as it awaits EU and U.S. approvals for Onpattro that should happen shortly.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,